Subtopic Deep Dive

ADAR-mediated A-to-I RNA editing in neurological disorders
Research Guide

What is ADAR-mediated A-to-I RNA editing in neurological disorders?

ADAR-mediated A-to-I RNA editing converts adenosine to inosine in RNA transcripts via ADAR enzymes, with dysregulation linked to neurological disorders including epilepsy, ALS, and autism.

ADAR1, ADAR2, and ADAR3 enzymes catalyze A-to-I editing, altering codon sequences and protein function in neuronal transcripts (Savva et al., 2012; 348 citations). Editing events target AMPA receptor GluR2 subunit, regulating synaptic plasticity and neuronal excitability (Wright and Vissel, 2012; 206 citations). Reduced editing occurs in Alzheimer's disease, affecting protein recoding (Khermesh et al., 2015; 149 citations).

Curated Papers

Key Challenges

Why It Matters

ADAR2-mediated editing of GluR2 prevents Ca2+ permeability in AMPA receptors, and its loss contributes to motor neuron death in ALS models (Wright and Vissel, 2012). Dysregulated editing in FMR1-related pathways associates with fragile X syndrome, impacting synaptic density (Shamay-Ramot et al., 2015). Studies link reduced A-to-I recoding to Alzheimer's pathology, suggesting therapeutic restoration targets (Khermesh et al., 2015). Editing influences CNS transcript diversification, affecting disease development in epilepsy and autism (Tariq and Jantsch, 2012).

Key Research Challenges

Detecting disease-specific editing sites

Identifying low-frequency A-to-I edits in heterogeneous neuronal tissues requires high-depth sequencing to distinguish from sequencing errors. Current methods struggle with brain region-specific editing patterns in disorders like epilepsy (Slotkin and Nishikura, 2013). Validation across patient cohorts remains inconsistent (Khermesh et al., 2015).

Linking edits to functional outcomes

Correlating specific ADAR editing events to altered protein function and neuronal excitability demands integrative multi-omics approaches. Challenges persist in modeling synaptic plasticity changes from GluR2 editing defects in ALS and autism (Wright and Vissel, 2012; Shamay-Ramot et al., 2015).

Therapeutic modulation of ADAR activity

Developing targeted activators or inhibitors for ADAR enzymes faces specificity issues due to widespread editing sites across coding and noncoding RNAs. Restoring editing in neurodegenerative contexts without off-target effects remains unsolved (Tariq and Jantsch, 2012).

Essential Papers

The ADAR protein family

Yiannis A. Savva, Leila E. Rieder, Robert A. Reenan · 2012 · Genome Biology · 348 citations

Adenosine-to-inosine RNA editing and human disease

William Slotkin, Kazuko Nishikura · 2013 · Genome Medicine · 300 citations

A-to-I RNA editing is a post-transcriptional modification that converts adenosines to inosines in both coding and noncoding RNA transcripts. It is catalyzed by ADAR (adenosine deaminase acting on R...

The essential role of AMPA receptor GluR2 subunit RNA editing in the normal and diseased brain

Amanda L. Wright, Bryce Vissel · 2012 · Frontiers in Molecular Neuroscience · 206 citations

α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors are comprised of different combinations of GluA1-GluA4 (also known asGluR1-GluR4 and GluR-A to GluR-D) subunits. The GluA2 subu...

Reduced levels of protein recoding by A-to-I RNA editing in Alzheimer's disease

Khen Khermesh, Anna Maria D’Erchia, Michal Barák et al. · 2015 · RNA · 149 citations

Adenosine to inosine (A-to-I) RNA editing, catalyzed by the ADAR enzyme family, acts on dsRNA structures within pre-mRNA molecules. Editing of the coding part of the mRNA may lead to recoding, amin...

The evolution and adaptation of A-to-I RNA editing

Arielle Yablonovitch, Patricia Deng, Dionna Jacobson et al. · 2017 · PLoS Genetics · 132 citations

Adenosine-to-inosine (A-to-I) RNA editing is an important post-transcriptional modification that affects the information encoded from DNA to RNA to protein. RNA editing can generate a multitude of ...

Inosine in Biology and Disease

Sundaramoorthy Srinivasan, Adrián Gabriel Torres, Lluı́s Ribas de Pouplana · 2021 · Genes · 115 citations

The nucleoside inosine plays an important role in purine biosynthesis, gene translation, and modulation of the fate of RNAs. The editing of adenosine to inosine is a widespread post-transcriptional...

The role of noncoding RNAs in Parkinson’s disease: biomarkers and associations with pathogenic pathways

Ming‐Che Kuo, Sam Chi-Hao Liu, Ya-Fang Hsu et al. · 2021 · Journal of Biomedical Science · 91 citations

Reading Guide

Foundational Papers

Start with Savva et al. (2012; 348 citations) for ADAR family mechanisms, Slotkin and Nishikura (2013; 300 citations) for disease associations, and Wright and Vissel (2012; 206 citations) for GluR2 editing in brain function—these establish core editing pathways and neurological relevance.

Recent Advances

Study Khermesh et al. (2015; 149 citations) on Alzheimer's recoding loss, Shamay-Ramot et al. (2015; 85 citations) on FMRP-ADAR in fragile X, and Srinivasan et al. (2021; 115 citations) for inosine roles in disease.

Core Methods

Core techniques include RNA-seq for G-to-A mismatch detection, ADAR knockdown models for functional validation, and bioinformatics for dsRNA structure prediction driving site-specific editing (Slotkin and Nishikura, 2013).

How PapersFlow Helps You Research ADAR-mediated A-to-I RNA editing in neurological disorders

Discover & Search

Research Agent uses searchPapers with query 'ADAR2 GluR2 editing ALS' to retrieve Wright and Vissel (2012), then citationGraph reveals 206 citing papers on AMPA receptor dysfunction, while findSimilarPapers expands to Khermesh et al. (2015) on Alzheimer's recoding deficits.

Analyze & Verify

Analysis Agent applies readPaperContent to extract editing site frequencies from Khermesh et al. (2015), verifies claims via CoVe against Slotkin and Nishikura (2013), and runs PythonAnalysis with pandas to quantify recoding reductions (149 vs. control sites), graded A via GRADE for statistical rigor.

Synthesize & Write

Synthesis Agent detects gaps in ADAR3 roles for neurodevelopmental disorders via contradiction flagging across Shamay-Ramot et al. (2015) and Tariq and Jantsch (2012); Writing Agent uses latexEditText for editing diagrams, latexSyncCitations for 10+ references, and latexCompile to produce a review section with exportMermaid flowcharts of editing pathways.

Use Cases

"Analyze editing site changes in Alzheimer's brain samples from Khermesh 2015"

Analysis Agent → readPaperContent (extracts recoding data) → runPythonAnalysis (pandas plots site frequencies vs. controls) → GRADE A-verified statistical summary with fold-change metrics.

"Draft LaTeX figure of ADAR2-GluR2 editing pathway in ALS"

Synthesis Agent → gap detection (Wright and Vissel 2012) → Writing Agent → latexGenerateFigure (AMPA receptor diagram) → latexSyncCitations → latexCompile (exports PDF with 5 citations).

"Find code for A-to-I editing detection in neuronal RNA-seq"

Research Agent → searchPapers (ADAR editing tools) → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect (delivers REDItools pipeline for site calling from Slotkin 2013-inspired datasets).

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers (250+ ADAR neurology papers) → citationGraph clustering → DeepScan 7-steps with CoVe checkpoints → structured report on editing deficits across ALS, Alzheimer's, fragile X. Theorizer generates hypotheses on ADAR modulation: analyzes Shamay-Ramot et al. (2015) FMRP interactions → flags contradictions with Wright and Vissel (2012) → proposes synaptic therapy models.

Try Doxa for ADAR-mediated A-to-I RNA editing in neurological disorders Research

Frequently Asked Questions

What defines ADAR-mediated A-to-I RNA editing?

ADAR enzymes (ADAR1-3) deaminate adenosine to inosine in dsRNA structures, read as guanosine during translation, altering codons in neuronal transcripts like GluR2 (Savva et al., 2012).

What methods detect A-to-I editing in disease?

High-throughput sequencing identifies inosine as G-to-A mismatches; tools quantify recoding sites in brain tissues from Alzheimer's patients (Khermesh et al., 2015).

What are key papers on ADAR in neurology?

Savva et al. (2012; 348 citations) reviews ADAR family; Wright and Vissel (2012; 206 citations) details GluR2 editing in brain disease; Slotkin and Nishikura (2013; 300 citations) links editing to human disorders.

What open problems exist in this field?

Challenges include brain-region specific editing maps, causal links to synaptic defects in autism/ALS, and ADAR-targeted therapies without off-target RNA effects (Tariq and Jantsch, 2012).